UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 494

Sortiert nach

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3212-3218

2013

Link zum Volltext

Verfügbarkeit prüfen

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Clinical cancer research, 2019-03, Vol.25 (6), p.1809-1816

2019

Link zum Volltext

Verfügbarkeit prüfen

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas

Scientific reports, 2021-10, Vol.11 (1), p.21133-8, Article 21133

2021

Link zum Volltext

Verfügbarkeit prüfen

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

Journal of clinical oncology, 2016-03, Vol.34 (7), p.731-739

2016

Link zum Volltext

Verfügbarkeit prüfen

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Neuro-oncology (Charlottesville, Va.), 2017-08, Vol.19 (8), p.1119-1126

2017

Link zum Volltext

Verfügbarkeit prüfen

Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells

Cancer biology & therapy, 2019-07, Vol.20 (7), p.979-988

2019

Link zum Volltext

Verfügbarkeit prüfen

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Neuro-oncology (Charlottesville, Va.), 2015-05, Vol.17 (5), p.708-717

2015

Link zum Volltext

Verfügbarkeit prüfen

Implementation and utilization of the molecular tumor board to guide precision medicine

Oncotarget, 2017-08, Vol.8 (34), p.57845-57854

2017

Link zum Volltext

Verfügbarkeit prüfen

RNA regulation of inflammatory responses in glia and its potential as a therapeutic target in central nervous system disorders

Glia, 2023-03, Vol.71 (3), p.485-508

2023

Link zum Volltext

Verfügbarkeit prüfen

A troublesome burden, the amplification of EGFR in glioblastoma

Neuro-oncology (Charlottesville, Va.), 2020-05, Vol.22 (5), p.594-595

2020

Link zum Volltext

Verfügbarkeit prüfen

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Journal of neuro-oncology, 2023-10, Vol.165 (1), p.101-112

2023

Link zum Volltext

Verfügbarkeit prüfen

Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions

Frontiers in immunology, 2024-02, Vol.15, p.1299044-1299044

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1651-1657

2007

Link zum Volltext

Verfügbarkeit prüfen

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Journal of neuro-oncology, 2018-05, Vol.138 (1), p.163-171

2018

Link zum Volltext

Verfügbarkeit prüfen

Hu antigen R (HuR) multimerization contributes to glioma disease progression

The Journal of biological chemistry, 2017-10, Vol.292 (41), p.16999-17010

2017

Link zum Volltext

Verfügbarkeit prüfen

When less is better: care of the elderly with glioblastoma

Neuro-oncology (Charlottesville, Va.), 2017-07, Vol.19 (7), p.879-879

Nabors, L Burt

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5610-5617

2008

Link zum Volltext

Verfügbarkeit prüfen

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors

Neurosurgery, 2019-09, Vol.85 (3), p.E607-E608

2019

Link zum Volltext

Verfügbarkeit prüfen

Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (12), p.1713-1714

2020

Link zum Volltext

Verfügbarkeit prüfen

College students' attitudes about ways family, friends, significant others and media affect their eating and exercise behaviors and weight perceptions

Journal of American college health, 2024-05, Vol.72 (4), p.1296-1308

2024

Link zum Volltext

Verfügbarkeit prüfen

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

Expert opinion on investigational drugs, 2008-08, Vol.17 (8), p.1225-1235

2008

Link zum Volltext

Verfügbarkeit prüfen

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery

Neuro-oncology (Charlottesville, Va.), 2020-10, Vol.22 (10), p.1422-1424

2020

Link zum Volltext

Verfügbarkeit prüfen

“It's Not Just the Seizures”: Brain Tumor Caregivers’ Experiences and Educational Needs in Out-of-Hospital Seizure Management

Journal of palliative care, 2023-07, Vol.38 (3), p.316-325

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

Molecular therapy, 2014-05, Vol.22 (5), p.1048-1055

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 494

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(451)
Mit Volltextzugriff
(455)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Implementation and utilization of the molecular tumor board to guide precision medicine

RNA regulation of inflammatory responses in glia and its potential as a therapeutic target in central nervous system disorders

A troublesome burden, the amplification of EGFR in glioblastoma

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions

Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Hu antigen R (HuR) multimerization contributes to glioma disease progression

When less is better: care of the elderly with glioblastoma

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors

Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics

College students' attitudes about ways family, friends, significant others and media affect their eating and exercise behaviors and weight perceptions

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

“It's Not Just the Seizures”: Brain Tumor Caregivers’ Experiences and Educational Needs in Out-of-Hospital Seizure Management

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

Suchergebnisse filtern